Skip to main content
Clinical Trials/NCT02965079
NCT02965079UnknownNot Applicable

Registry on the EXperience of Extracorporeal CO2 Removal in Intensive Care Units

Rexecor1 site in 1 country200 target enrollmentStarted: January 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
Incidence of ECCO2R use

Study Overview

Brief Summary

Investigators will aim to conduct an observational study in order to assess very thoroughly all patients implanted by Extracorporeal carbon dioxide removal (ECCO2R) in 10 critical care units of Paris and its surburb (APHP, Assistance Publique des hôpitaux de Paris).

Secondary objectives will be:

  1. to assess efficacy and safety of ECCO2R,
  2. to compare the data issue from the registry to others studies assessing the same population and to other centers and
  3. to compare the different ECCOR devices in terms of efficacy and adverse events.

Detailed Description

The registry will be conducted prospectively during 2 years in 10 ICUs of l'APHP on behalf on the CEDIT. The 10 centers are : (1) ICU of l'hôpital europeén Georges Pompidou, (2) ICU of l'Hôpital Louis Mourier, (3) ICU of l'Hôpital de Bicêtre, (4) ICU of GHPS, (5) Respiratory ICU of GHPS, (6) ICU of l'Hôpital Lariboisière (7) ICU of l'Hôpital Cochin (8) ICU of l'Hôpital Saint-Antoine (9)ICU of l'Hôpital Henri Mondor and (10) ICU of l'Hôpital Tenon.

The primary outcome will be the number of patients implanted by ECCO2R monthly in each center during the 2 years period study.

Secondary outcomes will be ICU-mortality, invasive ventilation duration, non invasive ventilation duration, ICU duration, modalities of ventilation at the ICU discharge, hemorragic complications due to the ECCOR device, thrombotic complications due to ECCO2R device, intravascular hemolysis due to ECCO2R device, duration of ECCO2R, adjunct therapy to ECCO2R and reasons of ECCO2R discontinuation.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients implanted with ECCCO2R

Exclusion Criteria

  • Contra-indication to ECCO2R

Outcomes

Primary Outcomes

Incidence of ECCO2R use

Time Frame: Recorded monthly up to 100 weeks (24 months)

Number of ECCO2R implantation monthly by center

Secondary Outcomes

  • Duration of mechanical ventilation(Recorded from ICU admission until the date of death or ICU discharge,assessed up to 100 weeks)
  • hemorragic and thrombotic complications(Recorded from the date of ECCO2R implantation until the removal of the device,assessed up to 100 weeks)
  • ICU mortality(Recorded From date of ICU admission until the date of death or ICU discharge, assessed up to 100 weeks)
  • ICU duration(Recorded from ICU admission until the date of death or ICU discharge,assessed up to 100 weeks)
  • Ventilation modalities at discharge(Recorded from the initiation of ventilation until ventilation removal,assessed up to 100 weeks)
  • hemolysis(Recorded from the date of ECCO2R implantation until the removal of the device,assessed up to 100 weeks)

Investigators

Sponsor
Rexecor
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials